Find an expert

My research concerns i) understanding causes and impacts of hearing impairment, particularly in the context of multimorbidity in older age, ii) prevention and treatment of hearing impairment, and iii) hearing service development and evaluation. My research involves epidemiological modelling with population data sets, clinical trials and hearing health policy. I have authored over130 publications in peer reviewed journals and books, and I frequently present invited and keynote addresses at international conferences. I have received the British Society of Audiology’s TS Littler prize for services to audiology and a prestigious US-UK Fulbright award.

I have been awarded 10 grants as principal investigator in the last 5 years totalling >AUD$14.5 million from competitive sources including the NHMRC, the NIHR, the Alzheimer’s Society UK, the European Commission, industry and charity funders. This funding includes an EU Horizon 2020 grant of €6.2 million (as joint PI for “Ears, Eyes and Mind: The “SENSE-Cog Project” to improve mental well-being for elderly Europeans with sensory impairment”), and two NHMRC Medical Research Future Fund awards ($1.2 million as CI for “SENSEcog aged care: Hearing and vision support to improve quality of life for people living with dementia in residential aged care”; AUD$1.3 million for "Home hearing and vision care to improve quality of life for people with dementia and carers"; and an AUD$0.9 million NHMRC targetted hearing research award (as CI for "Improving access to the hearing services program for people from culturally and linguistically diverse backgrounds"). I have strong links with hearing industry partners and have received research funding (total >AUD$500,000) from major hearing aid companies Starkey, Oticon, Phonak and the hearing industry research consortium. I have a position at the University of Manchester with on-going involvement (as CI and co-I) in projects funded by the NIHR, the ESRC, the Alzheimer’s Society and the RNID.

Professor Layton is a national leader in innovative ophthalmology, with expertise in macular disease, lens surgery and minimally invasive glaucoma interventions. He completed ophthalmology training in Queensland, Oxford and London, subspecialty training in retinal disease at the Royal Brisbane Hospital and holds a PhD in diabetic retinopathy from Oxford University. Professor Layton is a Rhodes Scholar and founding director of the LVF Ophthalmology Research Centre in Brisbane, Australia. He is also CEO of Ocugene, a Queensland based biotech start-up which is commercialising his gene therapy technology targeting macular degeneration, uveitis and choroidal melanoma. Professor Layton is the listed inventor of multiple ophthalmic patent applications currently under review in the USA, the EU, Japan, Israel, Australia and Singapore. He has published extensively in the international literature and his work has been recognised by awards from international eye research organisations.